The skin gateway
to the Immune System

What's New ?

April, 16 2014


DBV Announces the First reported case of a long term sustained effect of Peanut desensitization after Epicutaneous Immunotherapy (EPIT) with Viaskin® at the French Congress of Allergy

DBV Announces the First reported case of a long term sustained effect of Peanut desensitization after Epicutaneous Immunotherapy (EPITTM) with Viaskin® at the French Congress of Allergy  

More

A revolutionary approach in allergy treatment

11 to 26 million people suffer from food allergy in Europe while at the global level, the estimate is 220 to 500 million people. 3 to 5% of Americans suffer from food allergies and the prevalence of peanut allergy in children has almost quadrupled from 1997 to 2008…

EPIT Method Video

Missing flash plugin. Please download the latest Adobe Flash Player:
Get Adobe Flash Player

A short animation film explaining how DBV uses the Epicutaneous Immunotherapy with its VIASKIN patch to desensitize allergic patients

Legal Mention

CNIL number: 1544201 v 0

DBV technologies - siège social
Green Square - Bâtiment D
80/84 rue des Meuniers
92220 Bagneux
France
Phone: +33 (0)1 55 42 78 78
Fax: +33 (0)1 43 26 10 83

SIRET: 441772522 00013
RCS: Nanterre

Executive editor: Pierre-Henri Benhamou

Hosting service: OVH www.ovh.com

Design : l’enchanteur www.lenchanteur.com

Contact